City Therapeutics, based in Cambridge, is developing new medicines that use RNA interference, or RNAi, to silence genes and ...

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

City Therapeutics has launched with $135 million and Alnylam’s former CEO leading the charge as it develops a pipeline of ...

The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.

City Therapeutics launches with $135M to lead the future of RNAi-based medicine; led by founding Alnylam CEO and RNAi pioneer ...

Scholar Rock yesterday reported that its experimental treatment for spinal muscular atrophy succeeded in a Phase 3 trial, ...

City Therapeutics has announced its launch accompanied by a $135m Series A financing to lead advancements in RNAi-based ...

London-based startup Basecamp Research has closed a $60 million Series B round that will help expand its genomic database and ...

Poll Finds Harris Rising as She Challenges Trump on Change A national Times/Siena poll found Kamala Harris narrowly leading Donald Trump. Voters were more likely to see her, not Mr. Trump, as a ...

The JTN-NN show highlights important news of the week, with a focus on investigative journalism. Watch weeknights at 6 pm ET.